Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, GLP-1RA, Other Oct 03 | 2023EASD 2023 Key Press Releases (Oct 03)Purchase Blast$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other Oct 02 | 2023EASD 2023 Key Press Releases (Oct 02)Purchase Blast
$599
Posted in: GLP-1RA, Other Sep 29 | 2023Structure Announces Positive Topline Results from Ph1b Oral GLP-1RA Study; Better Therapeutics Completes Enrollment of AspyreRX Clinical Program in T2DM; Madrigal Commences $500M Public OfferingPurchase Blast
$599
Posted in: DPP-IVi, GLP-1RA, Other, SGLT2i Sep 28 | 2023Ozempic Label Update; AZ, BMS, Merck, and BI to Participate in Medicare Price Negotiations; FDA and Health Canada Clear Expansion Portion of Biomea’s Ph2 Oral Menin Inhibitor Trial in T2DMPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Sep 27 | 2023Rockley Photonics Progresses Non-Invasive, Optical Blood Glucose Monitoring; Intercept to be Acquired by Alfasigma; EMA to Discuss GLP-1RA-Associated Aspiration Risks; Kallyope Initiates Ph2 trial of Oral Obesity and T2DM TreatmentPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Sep 26 | 2023Novo Partners with Valo Health for CVD and Evotec for Cardiometabolic Drug Discovery Accelerator; Zucara Doses First Patient in Ph2a ZONE Trial; Merck Initiates Efinopegdutide Study in Hepatic Impairment; Senseonics Completes Adult Arm of ENHANCE Pivotal Study; NeuroBo Posts Ph2 DA-1241 Trial in NASH to CT.govPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i Sep 25 | 2023FDA Approves Jardiance for Adults with CKD; Abbott Completes Bigfoot Acquisition; Insulet Publishes “Market Opportunity & Impact of GLP-1s” Presentation; Lilly initiates Ph3 H2H Orforglipron vs. Semaglutide and New Ph3b Tirzepatide Max Dose Study in ObesityPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Sep 21 | 2023ITCA 650 Negative Adcom Vote; Medtronic Receives CE Mark for Simplera; 89bio’s Pegozafermin in NASH Receives Breakthrough Therapy Designation; Dexcom Canada Partners with RxFood for Diabetes Management; Novo Nordisk Foundation to Establish New Cell Therapy FacilityPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Sep 21 | 2023Ypsomed Signs Long-Term Autoinjector Supply Deal with Novo; Lilly Files Lawsuits Over Copycat Mounjaro ProductsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Sep 19 | 2023ITCA 650 Faces Uphill Battle as FDA Releases Adcom Briefing Docs; Novo Receives Form 483 Observations; Abbott and WeightWatchers Launch Connected App ExperiencePurchase Blast
$599
Posted in: Dual/triple agonist, Insulin Delivery, Other Sep 18 | 2023Novo Hires Private Contract Manufacturer for Wegovy Assembly and Packaging; Roche's Tubeless Patch Pump System Receives 510(k) Clearance; Beta Bionics Introduces iLet Bionic Pancreas; NeuroBo Doses First Patient for Ph2a DA-1241 Study in NASHPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other Sep 14 | 2023Lilly Initiates New Ph2 Study Investigating High Doses of Tirzepatide in Patients with T2DM and Obesity; Gan & Lee Doses First Patient in Ph2 QW Insulin Study; BMS discontinues NASH assetPurchase Blast
$599
Posted in: Glucose Monitoring, Other Sep 13 | 2023Madrigal Receives Priority Review for Resmetirom NASH NDA; Adipo Therapeutics Appoints Keith Johns as CSO; Novo Nordisk Conducts a Two-for-One Stock Split; Nemaura Announces Interim Miboko Study ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Sep 12 | 2023Entera Bio to Collaborate with OPKO Biologics for Obesity; Dexcom Launches Dexcom ONE in France; Altimmune Completes Ph2 Obesity Trial Dosing; Vertex Acquires Novel GPCR-targeted ProgramPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i Sep 11 | 2023September CHMP Agenda; Nemaura Announces Interim 24-Hour Wear sugarBEAT Results; Madrigal Appoints Bill Sibold as CEOPurchase Blast
$599
Posted in: Other Sep 07 | 2023Roche and Alnylam Report Topline Ph2 Hypertension Results; ITBMed Initiates Ph2 Siplizumab Study in New Onset T1DM PatientsPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Sep 06 | 2023FENIX Analysis: Thoughts on the Abbott/Bigfoot Acquisition - A New Era for the CGM and Insulin Delivery Market?Purchase Blast
$599
Posted in: Dual/triple agonist, Other Sep 06 | 2023Novo Partners with Broad Institute of MIT and Harvard for T2DM; Viking Initiates Ph2 Dual Agonist Obesity Trial; Cytokinetics Initiates Ph3 Aficamten Trial in Non-Obstructive HCMPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Sep 05 | 2023Abbott to Acquire Bigfoot; Novo Launches Wegovy in UK; Sernova and Glyscend Appoint New CEOs; SomaLogic Expands Agreement with Novo Through 2025; Novo’s Biocorp Acquisition Updates; Diamyd to Initiate Ph3 DIAGNODE-3 in USPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
